Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia

Urology

Volumn 58, Issue 2, 2001, Pages 203-208

  Baldwin, Kelly C ^a   Ginsberg, Phillip C ^a   Roehrborn, Claus G ^b   Harkaway, Richard C ^a,c  

^a ALBERT EINSTEIN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; FINASTERIDE;

AGED; ALPHA ADRENERGIC RECEPTOR BLOCKING; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG WITHDRAWAL; HUMAN; MAJOR CLINICAL STUDY; MALE; ORGAN SIZE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; TREATMENT OUTCOME; URINARY TRACT DISEASE;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; DOXAZOSIN; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FINASTERIDE; HUMANS; MALE; PROSTATIC HYPERPLASIA; TREATMENT OUTCOME;

EID: 0034899266     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(01)01201-8     Document Type: Article

References (18)

1. The development of human benign prostatic hyperplasia with age
2. High prevalence of benign prostatic hypertrophy in the community
3. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials
4. Maximum efficacy of finasteride is obtained within 6 months
5. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia
6. Evaluation of tissutal effects of finasteride on BPH
7. Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation on patients with benign prostatic hyperplasia
8. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia
9. A trial of the use of finasteride and terazosin in patients with benign prostatic hyperplasia
10. Peak flow and IPSS changes in patients treated with a combination of finasteride and terazosin after withdrawing terazosin
11. Comparative study of therapeutic effect of Dibenzyline, finasteride, and combination drugs for symptomatic benign prostatic hyperplasia
12. Results of PREDICT (Prospective Randomized European Doxazosin and Combination) study of medical therapy for BPH
13. Combination medical therapy for symptomatic benign prostatic hyperplasia
14. Use of a prostate model to assist in training for digital rectal examination
15. Correlation between prostate size estimated by digital rectal exam and measured by TRUS
16. Discontinuation of alpha blockade after initial treatment with finasteride and doxazosin for bladder outlet obstruction
17. Alpha blockade in the treatment of symptomatic benign prostatic hyperplasia